Request Demo

Last update 10 Sep 2026

Meloxicam

Last update 10 Sep 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryMeloxicam, a minuscule molecule drug, is classified as a COX-2 inhibitor, which selectively targets the COX-2 enzyme responsible for igniting the flames of inflammation and causing aches and agony. Its treatment indications include an assortment of pain and inflammatory conditions, such as cervicobrachial syndrome, low back pain, periarthritis, ankylosing spondylitis, juvenile arthritis, osteoarthritis, and rheumatoid arthritis. Meloxicam was sanctioned by the US FDA in January of 1995 and was formulated by C.H. Boehringer Sohn AG & Co. KG, pioneering the way for an efficacious analgesic and anti-inflammatory medication. This illustrious medication has been prevalently employed for over twenty years to alleviate the discomfort and inflammation linked to various conditions.

Drug Type

Small molecule drug

Synonyms

Meloxicam (JAN/USP/INN), Meloxicam-CPL-05, 美洛昔康-CPL-05

+ [29]

Target

COX-1 x COX-2

Action

inhibitors

Mechanism

COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Immune System DiseasesNervous System DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Pain, PostoperativeModerate painSevere pain+ [9]

Inactive Indication

Abdominal PainAcute pharyngitisAnkylosing Spondylitis+ [6]

Originator Organization

Cali (Shenzhen) Biosciences Co. Ltd.C.H. Boehringer Sohn AG & Co. KG

Active Organization

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.Nippon Boehringer Ingelheim Co., Ltd.

+ [10]

Inactive Organization

Boehringer Ingelheim Pharmaceuticals, Inc.

TerSera Therapeutics LLC

Joincare Pharmaceutical Group Industry Co., Ltd.

+ [5]

License Organization

Rxilient Health Pte Ltd.

Zyla Life Sciences LLC

Nanjing Qingpu Biotechnology Co., Ltd.

+ [3]

Drug Highest PhaseApproved

First Approval Date

Finland (27 Feb 1996)

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC14H13N3O4S2

InChIKeyZRVUJXDFFKFLMG-UHFFFAOYSA-N

CAS Registry71125-38-7

190

Clinical Trials associated with Meloxicam

IRCT20260321069008N1

/ CompletedPhase 3IIT

Investigating the effect of administration of Meloxicam tablet on sore throat after general anesthesia

Start Date10 May 2026

Sponsor / Collaborator

Zahedan University of Medical Sciences

JPRN-UMIN000060941

/ Not yet recruitingPhase 4IIT

Low-Dose Intrathecal Morphine in Multilevel Lumbar Spine Surgery: A Randomized Controlled Trial.

Start Date01 May 2026

Sponsor / Collaborator

King Abdullah Medical City

ChiCTR2600120556

/ SuspendedPhase 2IIT

To evaluate the efficacy and safety of a single local injection of GBI268 injection for postoperative analgesia in patients undergoing hemorrhoidectomy, a multicenter, randomized, double-blind, parallel controlled phase II clinical trial

Start Date18 Mar 2026

Sponsor / Collaborator

The Sixth Affiliated Hospital of Sun Yat-Sen University

[+1]

100 Clinical Results associated with Meloxicam

100 Translational Medicine associated with Meloxicam

100 Patents (Medical) associated with Meloxicam

3,810

Literatures (Medical) associated with Meloxicam

01 Oct 2026·THERIOGENOLOGY

Anti-inflammatory drugs disrupt granulosa cell homeostasis in vitro and impair bovine oocyte maturation and embryo development

Article

Author: Pietro, Riccaboni ; Giulia, Gaspari ; Fausto, Cremonesi ; Anna, Lange-Consiglio ; Susanna, Draghi ; Federica, Di Cesare ; Giampaolo, Bosi ; Linda, Ucci ; Petra, Cagnardi

Granulosa cells (GCs) play a crucial role in maintaining follicular homeostasis and supporting the acquisition of oocyte developmental competence. Disruption of GC function may therefore impair oocyte maturation and subsequent embryo development. Although anti-inflammatory drugs are widely used in cattle, their potential direct effects on follicular function and reproductive competence remain poorly understood. The aim of this study was to evaluate whether exposure of bovine GCs to non-steroidal anti-inflammatory drugs (NSAIDs) and a steroidal anti-inflammatory drug (SAID) affects GC viability and morphology, and whether these alterations influence oocyte maturation and embryo developmental competence in vitro. Bovine GCs were exposed to Meloxicam, Flunixin, and Ketoprofen (NSAIDs) or Dexamethasone (SAID) at different concentrations and exposure times. Cell viability and morphology following treatment were evaluated by acridine orange and MTT test. Functional consequences were investigated using a GC-oocyte transwell co-culture system to assess oocyte maturation through first polar body extrusion and subsequent embryo development in vitro. Dexamethasone induced the most pronounced alterations in GC morphology and monolayer integrity. All drug treatments significantly reduced (P < 0.05) the percentages of matured oocytes and blastocyst formation on day 7 compared with controls. On day 11 of embryo culture, Flunixin (5 μM, 8 h) and Ketoprofen (10 μM, 48 h) exerted the most severe effects, as no hatched blastocysts were observed. GC alterations were associated with impaired oocyte developmental competence and reduced embryo developmental potential. These findings suggest that exposure to anti-inflammatory drugs disrupts GC function and impairs oocyte developmental competence and embryo development in vitro.

01 Oct 2026·PREVENTIVE VETERINARY MEDICINE

Use of non-steroidal anti-inflammatory drugs for Finnish sows

Article

Author: Hokkanen, Ann-Helena ; Talvitie, Vera ; Ahlqvist, Kristina ; Holmström, Anna-Riia ; Hälli, Outi ; Valros, Anna ; Hedlund, Milla ; Heinonen, Mari ; Swan, Kirsi

Farrowing, diseases, and injuries all cause acute nociceptive pain to sows. Pain can strain the body, cause negative emotions and poor welfare, slow healing, and hinder piglet health and growth. Non-steroidal anti-inflammatory drugs (NSAIDs) are efficient and practical in alleviating nociceptive pain in sows, although more research about the efficiency, safety, and use in practice is needed. Thus, this observational, retrospective, cross-sectional, register-based study aimed to describe veterinary instructions for NSAID use in Finnish sow herds and to compare them with recorded use during January-December 2022. We also explored, using logistic regression, whether herd type or size was associated with NSAID use. A total of 70% of the 50 study herds had written veterinary instructions for NSAID use for sows. Although widespread, NSAID use was highly variable. Most herds administered pain alleviation to sows frequently, while five herds reported no NSAID use. Most often, ketoprofen or meloxicam was used to treat sows having anorexia without other symptoms, farrowing-related disorders and diseases, reproduction problems, or musculoskeletal diseases. Caretakers also administered NSAIDs for indications not instructed by the herd health veterinarian and used treatment durations longer than instructed. The median number (interquartile range, IQR) of total NSAID (ketoprofen plus meloxicam) treatment courses per sow was 0.35 (1.52), and the median number of NSAID doses used per 100 sows per day (NSAID_DDD_100) was 0.22 (IQR 0.58) in the study herds. Neither herd type nor herd size was associated with NSAID use.

01 Sep 2026·VETERINARY ANAESTHESIA AND ANALGESIA

Successful cardiopulmonary resuscitation after suspected mandibulocardiac reflex in a Jersey cow

Article

Author: Heppelmann, Maike ; Kästner, Sabine Br ; Wittenberg-Voges, Liza ; Sauer, Fay ; Brause, Stefanie ; Brumund, Lisa

General anaesthesia in cattle is associated with species-specific risks, while published data on anaesthesia-related morbidity, mortality, and cardiopulmonary resuscitation are sparse. This case report describes an intra-anaesthetic bradycardic cardiac arrest and resuscitation in a 17-month-old female Jersey cow scheduled for osteosynthesis of a right-sided mandibular fracture. Premedication consisted of xylazine [0.1 mg kg^-1 intramuscularly (IM) and 0.03 mg kg^-1 intravenously (IV)], butorphanol (0.05 mg kg^-1 IV), meloxicam (0.5 mg kg^-1 IV), and amoxicillin (10 mg kg^-1 IV). General anaesthesia was induced with ketamine (3 mg kg^-1 IV), maintained with isoflurane [end-tidal concentration (FE´Iso) 0.9%-1.3% in 100% oxygen], supplemented with a ketamine constant rate infusion (0.5 mg kg^-1 hour^-1 IV), and mandibular nerve block (lidocaine 0.45 mg kg^-1). Thirty-eight minutes after induction and 18 minutes after regional anaesthesia, during percutaneous needle placement along the mandibular fracture line, the cow developed sinoatrial block with ventricular escape rhythm and subsequent episodes of sinus tachycardia with hypertension. Following that, profound bradycardia progressed to cardiac arrest. Cardiopulmonary resuscitation (CPR) was initiated and included external chest compressions, controlled ventilation, and IV injections of epinephrine (0.01 mg kg^-1) and atropine (0.01 mg kg^-1). Return of spontaneous circulation occurred after three CPR cycles, followed by ventricular tachycardia, which was successfully treated with lidocaine (2 mg kg^-1, over 10 minutes). An arterial blood sample analysed at the time of the initial cardiovascular event, but evaluated retrospectively, revealed marked hyperkalaemia (8.1 mmol L^-1). Recovery from anaesthesia was uneventful, with no postanaesthetic abnormalities observed. This case suggests that, despite regional anaesthesia, activation of a mandibulocardiac reflex during minor mandibular manipulation, combined with temporary hyperkalaemia, may precipitate cardiovascular collapse. In adult cattle, prompt and structured CPR may be effective if cardiac arrest is rapidly diagnosed and immediate intervention is undertaken.

151

News (Medical) associated with Meloxicam

27 Jul 2026

·www.inno-n.com

HK inno.N Adds Sixth Indication for K-CAB — Broadest Label among P-CABs in South Korea

HK inno.N Adds Sixth Indication for K-CAB — Broadest Label among P-CABs in South Korea - Approval confirms efficacy in preventing peptic ulcers associated long-term NSAID use - Combined gastrointestinal protection and symptom relief reinforce K-CAB’s leadership in the P-CAB market - K-CAB 25 mg tested alongside 11 different NSAIDs, offering broad prescribing flexibility and a confirmed safety profile Photo. HK inno.N's novel drug series for gastroesophageal reflux disease, K-CAB HK inno.N has broadened the therapeutic reach of its gastroesophageal reflux disease (GERD) drug K-CAB (tegoprazan) with a sixth approved indication — non-steroidal anti-inflammatory drug (NSAID)-associated peptic ulcers — further cementing its leadership in the potassium-competitive acid blocker (P-CAB) drugs. The company announced on the 27th that the Ministry of Food and Drug Safety (MFDS) granted approval for a new indication of K-CAB, “the prevention of NSAID-associated peptic ulcers” With this latest approval for the new indication, K-CAB now carries six indications: treatment of erosive GERD; treatment of non-erosive GERD; treatment of gastric ulcers; eradication of H. pylori concurrently given with appropriate antibiotic therapy in patients with peptic ulcer and/or chronic atrophic gastritis; maintenance of healed erosive GERD; and prevention of NSAID-associated peptic ulcers (gastric and/or duodenal ulcers). This gives K-CAB the broadest indication profile among the P-CAB class drugs. The expanded label solidifies K-CAB’s standing as the leader of the P-CAB market. With NSAID use rising in step with aging populations and the growing prevalence of chronic pain, K-CAB is expected to introduce a much-needed alternative in a segment long dominated by proton pump inhibitors (PPIs) for concomitant prescribing, enabling patients to focus on their underlying condition without the burden of gastrointestinal side effects. The clinical trial supporting the new indication was conducted in patients on long-term NSAID therapy. The trial compared K-CAB 25 mg with lansoprazole 15 mg, a PPI, to evaluate efficacy and safety in the prevention of gastric and duodenal ulcers. On the primary efficacy endpoint — the incidence of gastric and duodenal ulcers at 24 weeks — K-CAB demonstrated non-inferiority to lansoprazole. At 12 weeks, a heartburn-free rate was significantly greater in the K-CAB arm compared with the lansoprazole arm. The trial participants were treated with a total of 11 different NSAIDs, underscoring K-CAB’s prescribing flexibility and safety. These comprised eight non-selective NSAIDs, including pelubiprofen, naproxen and meloxicam, and three COX-2 selective inhibitors, including celecoxib. K-CAB’s safety was also confirmed over 24 weeks of continuous administration. “The management of gastrointestinal complications from long-term NSAID use has been a significant unmet medical need worldwide,” commented Dal-won Kwak, CEO of HK inno.N. “The robust clinical evidence generated for this new indication is expected to serve as a key catalyst for K-CAB’s quantum leap into a blockbuster new drug in both the domestic and global markets.” K-CAB, the 30th homegrown new drug in South Korea, has led the domestic outpatient prescription market for peptic ulcer treatment since its launch in March 2019, driven by its rapid onset of action and demonstrated safety over six months of continuous use. In April, it became the first single-agent domestically developed new drug to surpass KRW 1 trillion in cumulative outpatient prescription sales. K-CAB has been out-licensed or supplied under finished drug product export agreements in 55 countries and is currently marketed in 20 markets, including South Korea, China and several Latin American countries, where its efficacy and excellence continue to be recognized. In January this year, HK inno.N’s U.S. partner Sebela Pharmaceuticals submitted a New Drug Application to the U.S. Food and Drug Administration (FDA), paving the way for K-CAB’s upcoming launch in the world’s largest pharmaceutical market. (END) (Reference Information) P-CAB (Potassium Competitive Acid Blocker / HK inno.N K-CAB (Tegoprazan)) - The mechanism of P-CAB is to block the secretion of gastric acid by competitively binding directly to the potassium ions of the proton pump without the need for activation by gastric acid; i.e., by interfering with the binding of potassium ions to the proton pump. - Therefore, P-CAB can be administered irrespective of food, provide a fast, strong effect of inhibiting gastric acid secretion from the first day of dosing, and have a long-acting property, compared to PPIs, ensuring superior prevention of overnight gastric acid secretion. Proton Pump Inhibitors (PPI) / lansoprazole, etc. - Gastric acid secretion is blocked by irreversible inhibition of the gastric proton pump (Hydrogen/Potassium Adenosine Triphosphatase; H+/K+-ATPase; Proton pump) involved in the final step of gastric acid secretion. - PPIs are prodrugs that are activated by gastric acid and then bind to the proton pump for inhibition of gastric acid secretion; therefore, they should be administered before food, with the maximal effect achieved after repeated administration (3 to 5 days).

Drug ApprovalClinical Result

04 Jun 2026

·www.biospace.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO ® data at the Americal Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at and follow us on LinkedIn and X . Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI ® , AUVELITY ® , and SYMBRAVO ® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

04 Jun 2026

·axsometherapeuticsinc.gcs-web.com

Axsome Therapeutics Presents New SYMBRAVO® Data at the American Headache Society (AHS) 68th Annual Scientific Meeting

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new SYMBRAVO® data at the American Headache Society (AHS) 68th Annual Scientific Meeting being held from June 4-7 in Orlando, FL. Details of the presentations are as follows: Title: SYMBRAVO (MoSEIC™ meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Return to Function Endpoint Analysis from MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Richard Lipton, MD, Professor of Neurology and Director of the Montefiore Headache Center, Albert Einstein College of Medicine, NY Poster Number: T19 Title: Comparative Efficacy of SYMBRAVO vs. Gepants for Acute Treatment of Migraine: A Network Meta-Analysis Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Stephanis Nahas, MD, MSEd, Professor of Neurology, Thomas Jefferson University, PA Poster Number: T24 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Treatment of Migraine: Sustained Pain Relief and Pain Freedom Among 2-Hour Responders in the Phase 3 MOMENTUM and MOVEMENT Trials Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Chia-Chun Chiang, MD, Assistant Professor of Neurology at the Mayo Clinic, Rochester, MN Poster Number: T30 Title: SYMBRAVO (MoSEIC meloxicam and rizatriptan) for the Acute Treatment of Migraine: Post-hoc Composite Efficacy and Safety Endpoint Analysis of INTERCEPT and MOMENTUM Presentation Date and Time: Thursday, June 4, 6:00 - 7:30 p.m. ET Lead Author: Fred Cohen, MD, Assistance Clinical Professor of Neurology, Icahn School of Medicine, Mount Sinai, NY Poster Number: T33 About Axsome Therapeutics Axsome Therapeutics is a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) conditions. We deliver scientific breakthroughs by identifying critical gaps in care and develop differentiated products with a focus on novel mechanisms of action that enable meaningful advancements in patient outcomes. Our industry-leading neuroscience portfolio includes FDA-approved treatments for major depressive disorder, agitation associated with dementia due to Alzheimer’s disease, excessive daytime sleepiness associated with narcolepsy and obstructive sleep apnea, and migraine, as well as multiple novel product candidates addressing a broad range of serious neurological and psychiatric conditions that impact over 150 million people in the United States. Together, we are on a mission to solve some of the brain’s biggest problems so patients and their loved ones can flourish. For more information, please visit us at www.axsome.com and follow us on LinkedIn and X. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the commercial success of the Company’s SUNOSI®, AUVELITY®, and SYMBRAVO® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the Company’s ability to successfully resolve any intellectual property litigation, and even if such disputes are settled, whether the applicable federal agencies will approve of such settlements; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the commercialization of SUNOSI, AUVELITY, and SYMBRAVO and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. Investors: Ashley Dong Senior Director, Investor Relations (929) 687-1614 adong@axsome.com Media: Darren Opland Senior Director, Corporate Communications (929) 837-1065 dopland@axsome.com

Phase 3NDA

100 Deals associated with Meloxicam

External Link

KEGG	Wiki	ATC	Drug Bank
D00969	Meloxicam	M01AC06	DB00814

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Pain, Postoperative	China	Nanjing Qingpu Biotechnology Co., Ltd.	30 Apr 2025
Moderate pain	United States	Nanjing Qingpu Biotechnology Co., Ltd.	22 Apr 2025
Severe pain	United States	Nanjing Qingpu Biotechnology Co., Ltd.	22 Apr 2025
Juvenile Idiopathic Arthritis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	11 Aug 2005
Juvenile Idiopathic Arthritis	United States	Avondale Pharmaceuticals LLC	11 Aug 2005
Cervicobrachial syndrome	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Low Back Pain	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Periarthritis	Japan	Nippon Boehringer Ingelheim Co., Ltd.	10 Sep 2004
Rheumatoid Arthritis	Australia	Boehringer Ingelheim Pty Ltd.	23 Feb 2001
Osteoarthritis	United States	Boehringer Ingelheim Pharmaceuticals, Inc.	13 Apr 2000
Pain	China	-	01 Jan 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Arthralgia	Phase 3	United States	Iroko Pharmaceuticals LLC	01 Feb 2013
Osteoarthritis, Knee	Phase 3	China	Boehringer Ingelheim GmbH	01 Jul 2004
Ankylosing Spondylitis	Phase 3	-	Boehringer Ingelheim GmbH	01 Jul 2001
Systemic onset juvenile chronic arthritis	Phase 3	Austria	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Belgium	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	France	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Germany	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Italy	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	Russia	Boehringer Ingelheim GmbH	01 Sep 2000
Systemic onset juvenile chronic arthritis	Phase 3	United Kingdom	Boehringer Ingelheim GmbH	01 Sep 2000

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06215820 (MR-107A-02, Pubmed \| Pain Ther)	Phase 3	-	397	MR-107A-02 15 mg (BID)	iqajmznfkx(dyrczytrjp) = mgwfsnqshz xxmrqahfps (okqbcfmqwx ) View more	Positive	27 Jul 2026
				Placebo	iqajmznfkx(dyrczytrjp) = hgohqrskky xxmrqahfps (okqbcfmqwx ) View more
NCT06306131 (CTgov)	Phase 2	Obesity	4	calcium carbonate 750 milligram (Placebo)	cklfhxaozr(xhxnjxsnkh) = dfqctsqgro hoeligetnb (byfynwfnek, 1.53) View more	-	30 Jun 2026
				Levonorgestrel 1.5 milligram+Meloxicam 15 milligram (Levonorgestrel Plus Meloxicam)	cklfhxaozr(xhxnjxsnkh) = mzzszbjcrs hoeligetnb (byfynwfnek, 0) View more
NCT05695352 (OVULATION, CTgov)	Phase 2	-	19	Placebo (Placebo Comparator in Normal Ovulatory Women)	sbjzcvebvp(dxfufrmmgl) = wnzukbmlps qsuklikglg (pypkoemogp, 2.24) View more	-	17 Jun 2026
				Levonorgestrel+meloxicam (Active Intervention in Normal Ovulatory Women)	sbjzcvebvp(dxfufrmmgl) = rllpevcgan qsuklikglg (pypkoemogp, 2.7) View more
NCT04115098 (Pubmed \| Rheumatology (Oxford))	Phase 2	Axial Spondyloarthritis	30	celecoxib	kusswjhhaw(fgzsojwgeo) = zkrolrdlex kdcogsmdyt (bcsuouuiej )	Positive	01 Dec 2025
				naproxen	kusswjhhaw(fgzsojwgeo) = xyljooumzz kdcogsmdyt (bcsuouuiej )
ACR2025	Not Applicable	Axial Spondyloarthritis	30	Celecoxib	zszbunvyns(zlthgenhzr) = Adverse events were infrequent and mild across all NSAIDs, with only one serious adverse event (diarrhea) reported. wpuqiydcaa (eocudprhcx ) View more	Positive	24 Oct 2025
				Meloxicam
NCT06215820 (Company_Website) Manual	Phase 3	Acute Pain	410	MR-107A-02 (bunionectomy subjects)	fakarpmxjw(rphwajtzzp): Difference (LS Mean) = 82.7 (95% CI, 62.0 - 103.4), P-Value = <0.001 View more	Positive	08 May 2025
				Placebo (bunionectomy subjects)
NCT06215859 (Company_Website) Manual	Phase 3	Acute Pain	579	MR-107A-02 (herniorrhaphy subjects)	zkapicmslr(qdpdzaccaj): Difference (LS Mean) = 50.1 (95% CI, 35.4 - 64.8), P-Value = < 0.001 View more	Positive	08 May 2025
				Placebo (herniorrhaphy subjects)
NCT05974501 (CTgov)	Phase 4	complications of arthroplasty \| Osteoarthritis, Knee \| Pain, Postoperative	84	Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Preoperative Adductor Canal Block Group)	xeuvnlnbmr(pooxmkmahl) = zekdcqnrfu zekgxtrtyt (gvpynglohh, iksgvpxjte - tfpydovwlc) View more	-	12 Feb 2025
				Lyrica+Ropivacaine+Acetaminophen+Oxycodone+Dexamethasone+Celebrex+Meloxicam (Postoperative Adductor Canal Block Group)	xeuvnlnbmr(pooxmkmahl) = masrubiwxl zekgxtrtyt (gvpynglohh, zjaipaydfw - ygktzqdmms) View more
CTR20222580 (Pubmed)	-	Pain, Postoperative	132	美洛昔康-QP001	ehbbxoicvc(hslmrzsula) = mbsixlkhtr rhijjuxpqg (fndupilkkz )	Positive	01 Oct 2024
				安慰剂	ehbbxoicvc(hslmrzsula) = jggwgyodsh rhijjuxpqg (fndupilkkz )
NCT05291598 (CTgov)	Phase 3	Pain	223	Ketorolac (Ketorolac Group)	qpuybxjyyu(uvqpipjcmo) = ptwplroneh sofajevmtn (nsyfizfgwy, 3.25) View more	-	14 Aug 2024
				IV meloxicam (IV Meloxicam Group)	qpuybxjyyu(uvqpipjcmo) = ldimesyjri sofajevmtn (nsyfizfgwy, 3.39) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis